Saturday, October 3, 2026

GBP/EUR Bearish Momentum With A 1% Fall In The Last 10 Sessions

GBP/EUR Bearish Momentum With A 1% Fall In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.06% for the last 10 sessions. At 04:10 EST on Friday, 21 July, GBP/EUR (GBPEUR) is $1.16.

GBP/EUR's yearly highs and lows, it's 6.945% up from its 52-week low and 3.545% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.24%, a negative 0.03%, and a positive 0.26%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.28% (last week), 0.29% (last month), and 0.26% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy struggles to gain any meaningful traction, holds steady near 139.00 mark. According to FXStreet on Wednesday, 19 July, "This has been a key factor behind the recent corrective decline in the US Treasury bond yields, which keeps the USD bulls on the defensive and might cap the upside for the USD/JPY pair.", "The underlying bullish sentiment surrounding the global equity markets undermines the safe-haven Japanese Yen (JPY) and turns out to be a key factor lending some support to the USD/JPY pair. "
  • Usd/jpy price analysis: not out of the woods yet, bearish flag spotted on hourly charts. According to FXStreet on Wednesday, 19 July, "Furthermore, oscillators on the daily chart are holding deep in the negative territory and validate the negative outlook for the USD/JPY pair.", "Apart from this, a modest US Dollar (USD) uptick is seen as a key factor lending some support to the USD/JPY pair. "
  • Usd/jpy justifies risk-barometer status above 139.00, ignores softer yields, fed bias. According to FXStreet on Wednesday, 19 July, "Furthermore, fears surrounding Japan Prime Minister (PM) Fumio Kishida's cabinet reshuffle and pessimism among the big industrial houses from Tokyo weigh on the Japanese Yen (JPY) and favor the USD/JPY bulls.", "However, the US 10-year and two-year Treasury bond yields stay pressured at 3.76% and 4.74% by the press time and prod the USD/JPY bulls of late."
  • Usd/jpy is understandably recovering some lost ground – MUFG. According to FXStreet on Wednesday, 19 July, "The renewed bounce in USD/JPY was in part triggered by comments from Governor Ueda at the G20 summit in India on Tuesday. ", "But in a backdrop of improved risk appetite and soft-landing optimism, USD/JPY is understandably recovering some lost ground."
  • Usd/jpy technical analysis: the rebound to the upside lacks momentum - 19 July 2023. According to DailyForex on Wednesday, 19 July, "According to the performance on the daily chart below, the price of the USD/JPY currency pair is still in attempts to rebound upwards, and the bulls' control over the trend will strengthen if the currency pair returns to the resistance levels of 140.50 and 141.70, respectively.", "Currently, the closest levels of support for the USD/JPY are 138.45 and 137.00, respectively. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com